首页> 外文期刊>Cancer genetics and cytogenetics >Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.
【24h】

Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion.

机译:伊马替尼敏感性慢性粒单核细胞白血病和t(5; 16)(q33; p13),PDGFRB-NDE1融合患者的PDGFRB阴性细胞中的三体性8。

获取原文
获取原文并翻译 | 示例
           

摘要

The development of clonal chromosome abnormalities in Philadelphia chromosome-negative (Ph.-) cells is well documented in chronic myeloid leukemia (CML) responding to interferon-a [1] and imatinib [2]. More recently, this phenomenon was observed after administration of two second-generation tyrosine kinase inhibitors, nilotinib and dasatinib [3,4]. Fusion involving the platelet-derived growth factor receptor 3 gene (PDGFRB) and a variety of partner genes has been identified in a fraction of Ph-chronic myeloprolif-erative disorders (CMPD) [5]. In these patients, the leukemo-genic fusion transcript results in constitutive tyrosine kinase activity that is usually sensitive to imatinib [6]. We recently identified a novel PDGFRB translocation partner (i.e., the gene NDE1) in a patient affected by chronic myelomonocytic leukemia carrying a translocation t(5; 16)(q33;p 13) [7]. Here, we describe the clinical evolution in this patient, who proved to be sensitive to imatinib and who developed a clone with trisomy 8 in PDGFRB-negative cells.
机译:在对干扰素-a [1]和伊马替尼[2]应答的慢性粒细胞白血病(CML)中,费城染色体阴性(Ph.-)细胞中克隆染色体异常的发生已得到充分证明。最近,在服用两种第二代酪氨酸激酶抑制剂尼洛替尼和达沙替尼后观察到了这种现象[3,4]。一部分血小板慢性增生性疾病(CMPD)中已鉴定出涉及血小板衍生的生长因子受体3基因(PDGFRB)和多种伴侣基因的融合[5]。在这些患者中,白血病基因融合转录本导致通常对伊马替尼敏感的组成型酪氨酸激酶活性[6]。最近,我们在患有易位t(5; 16)(q33; p 13)的慢性粒细胞性单核细胞白血病的患者中发现了一种新的PDGFRB易位伴侣(即基因NDE1)[7]。在这里,我们描述了该患者的临床进展,该患者被证明对伊马替尼敏感,并在PDGFRB阴性细胞中开发出具有8三体性的克隆。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号